Envestnet Asset Management Inc. Has $46.15 Million Holdings in argenx SE (NASDAQ:ARGX)

Envestnet Asset Management Inc. increased its stake in shares of argenx SE (NASDAQ:ARGX) by 10.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 75,037 shares of the company’s stock after purchasing an additional 7,146 shares during the period. Envestnet Asset Management Inc.’s holdings in argenx were worth $46,148,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Stifel Financial Corp boosted its position in argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after purchasing an additional 1,170 shares during the period. Stephens Inc. AR bought a new stake in shares of argenx during the 4th quarter worth $310,000. Ritholtz Wealth Management grew its stake in argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock valued at $552,000 after buying an additional 414 shares during the last quarter. Jones Financial Companies Lllp grew its stake in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after buying an additional 61 shares during the last quarter. Finally, MML Investors Services LLC raised its holdings in argenx by 16.9% in the 3rd quarter. MML Investors Services LLC now owns 8,699 shares of the company’s stock worth $4,715,000 after acquiring an additional 1,255 shares during the period. 60.32% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ARGX. Robert W. Baird upped their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a report on Tuesday, March 4th. Citigroup restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Guggenheim lifted their price target on argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Wells Fargo & Company increased their price objective on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Price Performance

Shares of ARGX stock opened at $546.22 on Friday. The stock’s fifty day simple moving average is $609.28 and its 200 day simple moving average is $603.68. argenx SE has a one year low of $352.77 and a one year high of $678.21. The firm has a market cap of $33.19 billion, a price-to-earnings ratio of -620.70 and a beta of 0.60.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, research analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.